share_log

复星医药(600196.SH):环丝氨酸胶囊获药品注册批准

Fosun Pharmaceutical (600196.SH): Cycloserine capsules approved for drug registration

Gelonghui Finance ·  Apr 24 05:05

Gelonghui, April 24 | Fosun Pharmaceutical (600196.SH) announced that the marketing registration application for cycloserine capsules (referred to as “the new drug”) independently developed by Shenyang Hongqi Pharmaceutical Co., Ltd., a holding subsidiary of the company, for the treatment of active tuberculosis and extrapulmonary tuberculosis (including renal tuberculosis) caused by tuberculosis bacteria sensitive to this drug and treated with first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin, and ethambutol) with poor treatment effects by first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin, and ethambutol), was recently approved by the State Drug Administration.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment